Transgenic non-human mammals and cells having a disruption in at least one allele of nArgBP2 are provided. Methods of identifying therapeutic agents for the treatment of a disorder associated with altered expression of nArgBP2 are also provided. Methods of assessing the risk of an individual developing a disorder associated with disruption of nArgBP2 and methods of treating individuals with such a disorder are provided.
GENES AND PATHWAYS INVOLVED IN BIPOLAR DISORDER